Overview
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
Status:
Completed
Completed
Trial end date:
2004-12-01
2004-12-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
We hypothesized that short-term treatment with AP drugs induces insulin resistance through a mechanistic route that is independent of weight gain and that atypical drugs exert stronger effects than typical compounds in this respect. We therefore treated healthy non-obese men with olanzapine (atypical AP) or haloperidol (typical AP) for 8 days, and studied the impact of these interventions on glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution technology and indirect calorimetry.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Leiden University Medical CenterCollaborator:
Dutch Diabetes Research FoundationTreatments:
Antipsychotic Agents
Dopamine
Haloperidol
Haloperidol decanoate
Olanzapine
Criteria
Inclusion Criteria:- Healthy men, with and without a positive family history of schizophrenia.
- 20 kg/m2 < BMI < 26 kg/m2
- Age 20-40 years
- Fasting plasma glucose < 6 mmo/L
Exclusion Criteria:
- FPG > 6 mmol/L
- BMI > 26 kg/m2
- Psychiatric disorders and/or use of antipsychotic or antidepressants drugs at present
or in the past.
- Any significant chronic disease
- Renal, hepatic or endocrine disease
- Use of medication known to influence lipolysis and/or glucose metabolism
- Total cholesterol > 7mmol/L and/or triglycerides > 2 mmol/L
- Recent weight changes or attempts to loose weight (> 3 kg weight gain or loss, within
the last 3 months)
- Difficulties to insert an intravenous catheter
- Smoking (current)
- Severe claustrophobia (ventilated hood)
- Recent blood donation (within the last 2 months)
- Recent participation in other research projects (within the last 3 months),
participation in 2 or more projects in one year
- Extensive sporting activities (more than 10 hours of exercise per week)